Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://jh.elmerpub.com

Original Article

Volume 14, Number 6, December 2025, pages 314-323

Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients – Real World Data from Hungary

Figures

Figure 1.
Figure 1. Study design.
Figure 2.
Figure 2. OS and PFS results in the whole intent-to-treat population. OS: overall survival; PFS: progression-free survival.
Figure 3.
Figure 3. OS and PFS results according to R-ISS. OS: overall survival; PFS: progression-free survival; R-ISS: Revised International Staging System.
Figure 4.
Figure 4. OS and PFS results according to cytogenetic alterations. OS: overall survival; PFS: progression-free survival.
Figure 5.
Figure 5. OS and PFS results according to frailty status. OS: overall survival; PFS: progression-free survival.
Figure 6.
Figure 6. OS and PFS results according to previous APSCT. APSCT: autologous peripheral stem cell transplantation; OS: overall survival; PFS: progression-free survival.
Figure 7.
Figure 7. OS and PFS results according to previous lenalidomide exposure. OS: overall survival; PFS: progression-free survival.

Tables

Table 1. Demographic and Clinical Characteristics of the Patient Population
 
Characteristic
APSCT: autologous peripheral stem cell transplantation; D-Rd: daratumumab, lenalidomide, and dexamethasone; Ig: immunoglobulin; R-ISS: Revised International Staging System.
Age at treatment onset (years), median (range)65 (41 - 78)
Gender, n (%)
  Male26 (47)
  Female29 (53)
Frailty status, n (%)
  Frail26 (47)
  Non-frail29 (53)
Type of measurable disease, n (%)
  IgG29 (52.7)
  IgA14 (25.4)
  Light-chain12 (21.9)
R-ISS disease staging, n (%)
  I16 (29)
  II11 (20)
  III28 (51)
Prior treatments, n (%)
  Bortezomib54(98)
  Thalidomide17 (31)
  Alkylating agent24 (44)
  APSCT23 (43)
  Lenalidomide maintenance9 (16)
Pre-D-Rd cytogenetic profile, n (%)
  Standard risk cytogenetic abnormality25/53 (47.1))
  High risk cytogenetic abnormality28/53 (52.9)

 

Table 2. Adverse Events
 
Grade 1 - 2Grade 3Grade 4Grade 5
Neutropenia254
Thrombocytopenia183
Anemia161
Infections15113
Gastrointestinal20
Infusion-related32
All126913

 

Table 3. Comparison of Baseline Patient Characteristics Across Clinical Trials Evaluating the Efficacy of D-Rd Therapy in Relapsed or Refractory Multiple Myeloma
 
POLLUX trialCzech Myeloma Group dataUS real-world dataHungarian National trial
aR-ISS staging system was used. D-Rd: daratumumab, lenalidomide, and dexamethasone; R-ISS: Revised International Staging System.
Number of patients28622421455
Previous treatment lines1 - 91 - 31 - 4+1
Age65 (34 - 89)65.5 (45.0 - 77.8)68.6 (41.2 - 83.4)65 (41 - 78)
ISS stages, n (%)
  1137 (48)89 (48.4)50 (23.4)16 (29)
  293 (32)41 (22.3)42 (19.6)11 (20)
  356 (20)54 (29.3)46 (21.5)28 (51)a
  Unknown40 (17.8)76 (35.5)
Cytogenetic alterations, n (%)Not reported
  Standard193 (67)163 (76.2)25 (45)
  High-risk35 (12)32 (15)28 (51)
  Unknown58 (21)19 (8.9)2 (4)
Frailty status, n (%)Not reportedNot reported
  Frail35 (16.4)26 (47)
  Non-frail179 (83.6)29 (53)